The goal of this Phase II clinical trial is to learn if the oral synthetic allopreganolone analog (zuranolone) is safe to take and is well tolerated by stroke survivors experiencing moderate to severe post-stroke depression and if it will help with the symptoms of depression. The main questions it will aim to answer are:
* Is zuranolone safe to take by participants who have moderate to severe post-stroke depression?
* Is zuranolone well-tolerated by participants who have moderate to severe post-stroke depression?
* Does zuranolone treat moderate to severe post-stroke depression?
The study will enroll six participants. All participants will be given 50 mg of zuranolone for 14 days.
Participants will be asked to provide blood samples, complete some questionnaires including those related to mood and a cognitive assessment.

Start Date01 Jul 2025

Sponsor / Collaborator

Duke University

[+1]

NCT07047820

/ Not yet recruitingNot Applicable

Prospective, Observational Survey Study Assessing Effectiveness of Zuranolone in Improving PPD Symptoms in the Real-world Setting

In this study, researchers will learn more about how zuranolone affects the symptoms of postpartum depression, also known as PPD. Zuranolone is a drug that healthcare professionals can prescribe for adults with PPD. After giving birth, adults with PPD can suffer from symptoms such as tiredness, sadness, and a loss of interest in their daily activities.
This study is known as an "observational" study, which means it collects health information about study participants after a healthcare professional has already prescribed treatment. Participants for this study will be found in the United States using a database from CVS Specialty Pharmacy. This will include anyone who was prescribed zuranolone between June 2025 and May 2026 and who filled the prescription within 1 year after the end of their pregnancy.
The main goal of this study is to learn more about how zuranolone affects the participants' PPD symptoms. This will be measured using a questionnaire completed by participants called the Edinburgh Postnatal Depression Scale, also known as the EPDS. A higher score on the EPDS may indicate more severe PPD symptoms.
The main question researchers want to answer in this study is:
- Do PPD symptoms change after treatment with zuranolone based on EPDS scores measured at Day 15?
Researchers will also learn more about:
* Changes in participants' EPDS scores from before treatment to Day 45, which is 30 days after treatment ends.
* How many participants breastfeed their babies while taking zuranolone
* How many participants do not start new medicine after finishing their zuranolone treatment
* How many participants take new medicines after finishing zuranolone
* How many participants already tried other medicines for their depression symptoms before joining this study
* How many participants take other medicines in general while taking zuranolone
This study will be done as follows:
People who fill their zuranolone prescription through CVS Specialty Pharmacy will be contacted by email or phone to ask them about their interest in participating in the study.
Those who agree to take part will answer written questions about their symptoms using the EPDS tool. They will also answer other survey questions about their background, environment, and general health information. Participants must take their first dose of zuranolone within 7 days of joining the study.
Participants will then be asked to answer questions using the EPDS tools, 15 days and 45 days after taking the first dose of zuranolone.

Start Date26 Jun 2025

Sponsor / Collaborator

Biogen, Inc.

NCT05655507

/ CompletedPhase 1

A Phase 1, Study to Evaluate the Pharmacokinetics and Safety of Zuranolone in Adolescents (12 to 17 Years of Age) With Major Depressive Disorder

The primary purpose of this study is to evaluate the pharmacokinetics and safety of Zuranolone in adolescents (ages 12 to 17 years) with MDD.

Start Date19 Apr 2023

Sponsor / Collaborator

Biogen, Inc.

100 Clinical Results associated with Zuranolone

100 Translational Medicine associated with Zuranolone

100 Patents (Medical) associated with Zuranolone

136

Literatures (Medical) associated with Zuranolone

01 Jul 2025·EUROPEAN NEUROPSYCHOPHARMACOLOGY

Racial and ethnic diversity in zuranolone and brexanolone clinical trials for postpartum depression: A cross-sectional analysis of ClinicalTrials.gov

Letter

Author: Pruc, Michal ; Szarpak, Lukasz ; Kwaśny, Aleksander ; Cubała, Wiesław Jerzy ; Swieczkowski, Damian

01 Jun 2025·Biotechnology reports (Amsterdam, Netherlands)

Unveiling the potential biochemical effects of selected heterocyclic compounds as human Type-A γ-aminobutyric acid (GABA A) Modulator: An Insilico Approach

Article

Author: Olanrewaju, Adesoji Alani ; Oyebamiji, Abel Kolawole ; Afolabi, Samson Olusegun ; Akinola, Omowumi Temitayo ; Erazua, Ehimen Anastasia ; Olaseinde, Ayodeji Arnold ; Adekunle, David O ; Akintelu, Sunday Adewale ; Ebenezer, Oluwakemi ; Olujinmi, Faith Eniola

Background:

Investigating the bioactivities of zuranolone derivatives as Type-A γ-aminobutyric acid inhibitors which will thereby down-regulate postpartum depression is considered a crucial study.

Method:

This study is aimed at investigating the biochemical activities of 1-(2-((3R,5R,8R,9R,10S,13S,14S,17S)-3‑hydroxy-3,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)-2-oxoethyl)-1H-pyrazole-4-carbonitrile derivatives against type-A γ-aminobutyric acid (GABA A) which will thereby enhance the activity of γ-aminobutyric acid (GABA) in human central nervous system.

Results:

In this work, series of computational tools such as Spartan 14, molecular operating environment software, Gromacs and Admetsar1 were explored and the studied compounds were subjected to this software which resulted to series of results. Vacuum was observed to have highest influence on highest occupied molecular orbital (E_H) of compound 1 and water as well as ethanol reduces its ability to donate electron to the nearby molecules. Also, the effect of water and ethanol were investigated on the studied compound via lowest unoccupied molecular orbital (E_L) and energy gap and the results were reported appropriately. The molecular docking investigation was carried out on the studied compounds and Type-A γ-aminobutyric acid (pdb id: 4cof) and the compounds 3 with calculated binding affinity value of -7.32433319kcal/mol as well as pi-H as the non-bonding interaction were observed which therefore confirm the potential ability of compound to inhibit the target than other studied compound. Also, compound 1 and reference compound were subjected to molecular dynamic simulation study and the actual binding energy for the selected compounds were obtained and reported.

Conclusion:

Our findings from this work may open door for the design of several 1-(2-((3R,5R,8R,9R,10S,13S,14S,17S)-3-(benzyloxy)-3,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)-2-oxoethyl)-1H-pyrazole-4-carbonitrile derivatives as potential Type-A γ-aminobutyric acid inhibitors.

01 May 2025·INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY

Understanding and treating postpartum depression: a narrative review

Review

Author: Carminati, Matteo ; Pecorino, Basilio ; Serretti, Alessandro ; Zanardi, Raffaella ; Tondello, Mattia ; Cardaci, Vincenzo

Postpartum depression (PPD) is an increasingly prevalent but still poorly characterized disorder. Causal and modulating factors include hormones fluctuations, such as estrogen, progesterone, and allopregnolone, pathways imbalances, such as oxytocin and kynurenine, chronobiological factors, and brain imaging alterations. Treatment may differ from the traditional major depression management, while selective serotonin reuptake inhibitors such as sertraline are commonly used and suggested by guidelines, neurosteroids such as brexanolone and the more convenient zuranolone have been recently approved. Newer neurosteroids such as ganaxolone, valaxanolone, and lysaxanolone are currently under development, but also esketamine and psychedelics are promising potential treatments. Other somatic treatments including brain stimulation techniques and light therapy also showed benefit. PPD is therefore increasingly understood as, at least partially, independent from major depressive disorder. Specific and individualized treatments including pharmacological and non-pharmacological therapies are progressively being introduced in the routine clinical practice.

240

News (Medical) associated with Zuranolone

03 Jul 2025

·www.biospace.com

Sage’s Search for Lifeline Ran Into Defiant Biogen CEO

iStock, wassam siddique After the FDA rejection of Zurzuvae in one type of depression and the triple failure of neuro asset dalzanemdor, Sage was searching for a path forward at the end of December 2024. Biogen CEO Chris Viehbacher spied a possible deal, but the smaller company wasn’t interested. After the FDA rejected one out of two indications for the depression drug Zurzuvae in the summer of 2023, Sage Therapeutics embarked on a whirlwind tour of the biotech fundraising universe to find a partner or other transaction to keep afloat. According to regulatory documents posted Wednesday, that meant meeting with 43 different parties throughout 2024 and into 2025. We now know that the result of that tour was the up to $795 million acquisition by Supernus Pharma , inked last month. The focus of the deal was Zurzuvae, which received an FDA nod for post-partum depression in August 2023, but missed out on the larger indication of major depressive disorder which would have opened up a much wider market. Sage had long been partnered with Biogen on the drug. The regulatory documents show how the Sage-Biogen relationship broke down after Zurzuvae’s mixed approval. Thanks But No Thanks After the FDA rejection, and the triple failure of leading pipeline candidate dalzanemdor, Sage was left searching for a path forward at the end of December 2024. The board was pursuing a royalty financing with an unnamed party, which would have provided as much as $200 million in capital. During a regularly scheduled meeting to discuss Zurzuvae commercialization efforts that month, Biogen CEO Chris Viehbacher raised the possibility of an acquisition with Sage CEO Barry Greene. At a board meeting later that month, Sage’s executives determined that a royalty transaction was prudent. But to do so, they would need Biogen’s cooperation. Days later, Viehbacher returned with a more concrete offer to acquire Sage at the current stock price plus a 30% premium. Greene declined the offer. In early January, the royalty transaction was advancing. Viehbacher reached out again, this time warning Greene that Biogen was about to put in an unsolicited offer to buy his company. Greene indicated that he believed public disclosure of this intention would violate the companies’ standstill provision from Biogen’s original stock purchase agreement. Viehbacher stood his ground. The offer was coming. On January 10, Biogen publicly offered to buy Sage for $7.22 per share, which was a 30% premium to the stock price that day of $5.55. The deal valued Sage at about $470 million. Sage acknowledged the offer in a press release. Sage formally filed a lawsuit against Biogen on January 16, arguing that the public disclosure was a violation of their standstill agreement . The board nevertheless agreed to consider Biogen’s offer. Greene and his deputies headed into the J.P. Morgan Healthcare Conference a few days later to meet with investors. Many encouraged them to accept the Biogen offer but push for more. Others suggested that Sage should seek to reacquire the rights to Zurzuvae, which had long been a hope of the Sage team. On January 27, Sage announced a plan to explore strategic alternatives , including consideration of a sale or other transaction. The board also at that time formally rejected Biogen’s offer. Meetings with potential buyers followed, including Supernus, who had long been in touch with Sage about a potential partnership or acquisition. During this period, shareholders put pressure on Sage’s management to do something to stop the cash burn and enter into some sort of deal—and quickly. They suggested that Sage drop its R&D pipeline, among other options. A court in late January sided with Sage in the standstill litigation, preventing Biogen from issuing any further public offers. They later settled the litigation. Greene and Viehbacher met again in February for their regularly scheduled meeting, during which Viehbacher indicated that Biogen would not put forward another bid. In the months that followed, Sage’s board and executives met with multiple parties and considered myriad partnering solutions. They considered chopping up the company and spinning out the pipeline; handing Zurzuvae rights to Biogen; selling the entire company and more. Supernus was one of the leading companies in the discussions and ultimately won out on June 13 with an offer of $8.50 per share in cash, or $561 million, at closing. A contingent value right put up another $3.50 per share, or $234 million, payable upon certain sales and commercial milestones. The deal was valued at up to $12 per share in cash or $795 million. Analysts that day called the Supernus acquisition a “good end” for Sage, but an “unremarkable outcome” for an entity that was once one of the most exciting companies working on central nervous system disorders. While management had been maneuvering in private for more than two years, staff at Sage had a more abrupt end; last week, all 338 remaining workers were sent out the door .

AcquisitionDrug Approval

16 Jun 2025

·pipelinereview.com

Supernus Pharmaceuticals to Acquire Sage Therapeutics, Strengthening its Neuropsychiatry Product Portfolio

ROCKVILLE, MD and CAMBRIDGE, MA, USA I June 16, 2025 I Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN) and Sage Therapeutics, Inc. (Nasdaq: SAGE), today announced a definitive agreement for Supernus to acquire Sage through a tender offer for $8.50 per share in cash (or an aggregate of approximately $561 million), payable at closing, plus one non-tradable contingent value right (CVR) collectively worth up to $3.50 per share in cash (or an aggregate of approximately $234 million), for total consideration of $12.00 per share in cash (or an aggregate of up to approximately $795 million). The CVR is payable upon achieving certain net sales and commercial milestones. The transaction is expected to close in the third quarter of 2025. The transaction will provide Supernus with an innovative marketed product: ZURZUVAE ® (zuranolone) capsules CIV, the first and only U.S. Food and Drug Administration (FDA)-approved oral medicine indicated for the treatment of adults with postpartum depression. Through a collaboration agreement with Biogen, Inc., Supernus will report collaboration revenue that is 50% of total net revenue Biogen records for ZURZUVAE in the U.S. “This acquisition represents a major step in bolstering our future growth. It augments our growth profile by adding a significant fourth growth product to our portfolio and further diversifies our sources of future growth. ZURZUVAE aligns with our focus of acquiring novel value-enhancing and clinically-differentiated medicines to treat CNS conditions,” said Jack Khattar, President and CEO of Supernus Pharmaceuticals. “We have a proven track record of strong commercial execution, and we look forward to building on ZURZUVAE’s U.S. growth momentum and collaboration with Biogen, so that more women with postpartum depression can benefit from this novel treatment.” “Since our founding, Sage Therapeutics has been committed to pioneering new solutions in brain health, one of the most complex and underserved areas of medicine,” said Barry Greene, Chief Executive Officer, Sage Therapeutics. “We are proud of what we’ve accomplished, including successfully developing and commercializing ZURZUVAE, the first and only oral treatment for women with postpartum depression. This transaction follows a comprehensive strategic review by our Board of Directors, and I am confident this deal maximizes value for shareholders. I want to express my deepest gratitude to the Sage team for their unwavering commitment to brain health and improving the lives of patients. We look forward to our next chapter with Supernus.” Strategic and Financial Benefits Terms and Financing Under the terms of the agreement, Supernus will commence a tender offer to acquire all outstanding shares of Sage Therapeutics, Inc. for a purchase price of $8.50 per share in cash (or an aggregate of approximately $561 million) payable at closing plus one non-tradable CVR. All cash consideration will be funded through existing balance sheet cash. The CVR entitles Sage stockholders to receive up to an additional $3.50 per share payable upon ZURZUVAE achieving certain sales and commercial milestones within certain specified periods (subject to the terms and conditions contained in a Contingent Value Rights Agreement detailing the terms of the CVR). These milestones include (1) $1.00 per share payable if in any calendar year between closing and end of 2027, annual net sales of ZURZUVAE allocable to Supernus reach $250 million or more in the U.S., (2) $1.00 per share payable if in any calendar year between closing and end of 2028, annual net sales of ZURZUVAE allocable to Supernus reach $300 million or more in the U.S., (3) $1.00 per share payable if in any calendar year between closing and end of 2030, annual net sales of ZURZUVAE allocable to Supernus reach $375 million or more in the U.S., and (4) $0.50 per share at first commercial sale in Japan to a third-party customer after regulatory approval for ZURZUVAE for the treatment of major depressive disorder (MDD) in Japan by June 30, 2026. Approvals and Timing of Close The transaction, which has been approved by the boards of directors of both companies, is expected to close in the third quarter of 2025, subject to customary closing conditions, including receipt of required regulatory approvals and the tender of a majority of the outstanding shares of Sage’s common stock. Following the successful closing of the tender offer, Supernus will acquire any shares of Sage that are not tendered in the tender offer through a second-step merger at the same consideration as paid in the tender offer. Full Year Financial Guidance Supernus will provide revised full year 2025 financial guidance after the closing of the transaction, which is expected in the third quarter of 2025. Advisors Moelis & Company LLC is acting as the exclusive financial advisor to Supernus. Goldman Sachs & Co. LLC is acting as the exclusive financial advisor to Sage. Saul Ewing LLP is serving as legal counsel to Supernus. Kirkland & Ellis LLP is serving as legal counsel to Sage. Conference Call and Webcast Information A conference call and a live webcast will be hosted today, June 16, 2025, at 8:30 a.m. ET, to discuss the transaction. A live webcast will be available in the Events & Presentations section of the Supernus Investor Relations website www.supernus.com/investors . Participants may also pre-register any time before the call here . Once registration is completed, participants will be provided a dial-in number with a personalized conference code to access the call. Please dial in 15 minutes prior to the start time. Following the live call, a replay will be available on the Supernus Investor Relations website www.supernus.com/investors . The webcast will be available on the Supernus website for 60 days following the live call. About Supernus Pharmaceuticals, Inc. Supernus Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. Our diverse neuroscience portfolio includes approved treatments for attention-deficit hyperactivity disorder (ADHD), dyskinesia in Parkinson’s disease (PD) patients receiving levodopa-based therapy, hypomobility in PD, epilepsy, migraine, cervical dystonia, and chronic sialorrhea. We are developing a broad range of novel CNS product candidates including new potential treatments for epilepsy, depression, and other CNS disorders. For more information, please visit www.supernus.com . About Sage Therapeutics Sage Therapeutics (Nasdaq: SAGE) is a biopharmaceutical company committed to our mission of pioneering solutions to deliver life-changing brain health medicines, so every person can thrive. Sage developed the only two FDA-approved treatments indicated for postpartum depression and is advancing a pipeline to target unmet needs in brain health. Sage was founded in 2010 and is headquartered in Cambridge, Mass. Find out more at www.sagerx.com or engage with us on Facebook , LinkedIn , Instagram , and X . For more information about ZURZUVAE, please visit www.zurzuvae.com . SOURCE: Supernus Pharmaceuticals

Drug ApprovalAcquisition

16 Jun 2025

·www.biospace.com

Sage’s Story Comes to ‘Good End’ With Up To $795M Acquisition by Supernus

iStock, master1305 Stifel analysts said the deal “feels like an unremarkable outcome for a company that was once one of the hottest stories in CNS.” Supernus’ offer beats Biogen’s unsolicited bid of about $7.22 per share, which arrived with a thud in late January. Sage Therapeutics has agreed to be acquired by Supernus Pharmaceuticals for up to $795 million, marking a “good end” to the biotech’s story, according to analysts. The deal comes about five months after Sage balked at an unsolicited offer from its Zurzuvae development partner Biogen, which was valued at about $470 million. The companies announced the acquisition Monday morning . Supernus is offering $8.50 per share in cash, or $561 million, at closing. The deal also includes a non-tradable contingent value right (CVR) of $3.50 per share, or $234 million, payable upon certain sales and commercial milestones. That brings the deal, which is expected to close in the third quarter, up to $12 per share in cash or $795 million. Stifel analysts wrote in a note to investors that the deal “feels like an unremarkable outcome for a company that was once one of the hottest stories in [central nervous system disorders].” Nevertheless, it is a “good end” for the company, which had been facing myriad challenges including a lack of strategic control over lead asset Zurzuvae, the analysts said. The postpartum depression drug was developed with Biogen and received a limited label upon approval in August 2023. Sage’s shares rose 36% in premarket trading Monday morning to $9.17. The stock has fallen 41% over the past year after hitting a price of over $90 in 2021. Supernus’ offer beats Biogen’s unsolicited bid of about $7.22 per share, which arrived with a thud in late January. Sage immediately recoiled at the idea, suing Biogen to stop it. Stifel had assumed that Biogen would return with a “sweetened offer,” but that never happened. Either way, Stifel did not voice much hope for Sage continuing on its own. “As we see it, for Sage to create value as an independent company, it would’ve required either a substantial acceleration in the PPD launch, or a surprise to the upside from the pipeline—the latter being a higher risk strategy, and a ‘show me story for the street, that would’ve burned significant capital,” the analysts wrote. The deal does not put much weight in Sage’s pipeline, Stifel added. Supernus noted the potential of Zurzuvae to boost growth and diversify its portfolio. The drug, for postpartum depression, brought in $36.1 million in 2024 and has already taken home $13.8 million for the first quarter. The company also has three approved CNS medicines, Qelbree, ONAPGO and Gocovri, plus five other products. Supernus and partner Biogen will have to significantly grow Zurzuvae sales for shareholders to see any benefit from the CVR. They will receive $1 of the CVR if Zurzuvae reaches $250 million in a calendar year between now and 2027; $1 if it reaches $300 million between now and the end of 2028; and $1 if sales reach $375 million between now and the end of 2030. Another 50 cents per share will be allocated if Zurzuvae is approved in Japan for major depressive disorder and achieves an initial commercial sale there. The FDA declined to grant an indication for MDD, instead keeping the label narrowed to PPD. Sage CEO Barry Greene said in the company’s announcement that the deal concludes a strategic review conducted by the board of directors and he is “confident this deal maximizes value for shareholders.”

AcquisitionDrug Approval

100 Deals associated with Zuranolone

External Link

KEGG	Wiki	ATC	Drug Bank
D11793	Zuranolone	-	DB15490

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Depression, Postpartum	United States	SAGE Therapeutics, Inc.	04 Aug 2023
Depression, Postpartum	United States	Biogen, Inc.	04 Aug 2023

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Depressive Disorder	NDA/BLA	Canada	Biogen, Inc.	01 Dec 2024
Depressive Disorder, Major	NDA/BLA	United States	SAGE Therapeutics, Inc.	-
Sleep Initiation and Maintenance Disorders	Phase 3	United States	Biogen, Inc.	04 Feb 2019
Bipolar I disorder	Phase 2	United States	SAGE Therapeutics, Inc.	23 Aug 2018
Bipolar I disorder	Phase 2	United States	Biogen, Inc.	23 Aug 2018
Bipolar II disorder	Phase 2	United States	Biogen, Inc.	23 Aug 2018
Bipolar II disorder	Phase 2	United States	SAGE Therapeutics, Inc.	23 Aug 2018
Essential Tremor	Phase 2	United States	Biogen, Inc.	24 Mar 2017
Parkinson Disease	Phase 2	United States	Biogen, Inc.	30 Nov 2016
Seizures	Phase 1	United States	SAGE Therapeutics, Inc.	-

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03864614 (SHORELINE Study, Pubmed \| J Clin Psychiatry)	Phase 3	Depressive Disorder, Major	-	Zuranolone 30mg	vfchgukgvm(mkvewshdws) = Of patients who experienced TEAEs, most reported mild or moderately severe events, and responders to zuranolone experienced improvements in depressive symptoms with initial and repeat treatment courses wzyffgxhuc (guampfmxqn )	Positive	27 Dec 2023
				Zuranolone 50mg
NCT04442490 (CTgov)	Phase 3	Depressive Disorder, Major	543	Placebo (Placebo)	qtccowtvic(znytuujizc) = jcddqngcon oedbrhqrfe (lutvbnnpkw, 0.50) View more	-	05 Dec 2023
				SAGE-217 (SAGE-217 50 mg)	qtccowtvic(znytuujizc) = uyoqflpkse oedbrhqrfe (lutvbnnpkw, 0.51) View more
NCT04476030 (CTgov)	Phase 3	Depressive Disorder, Major	440	Escitalopram+Matching Placebo+Desvenlafaxine+sertraline+Duloxetine+Citalopram (Placebo + Assigned ADT)	uktqjovlra(icowzhmbls) = tqxysxdcro dqtiojkrcb (pmjxkooanr, 0.38) View more	-	07 Nov 2023
				Escitalopram+Desvenlafaxine+sertraline+Duloxetine+SAGE-217+Citalopram (SAGE-217 + Assigned ADT)	uktqjovlra(icowzhmbls) = zjyrxntpek dqtiojkrcb (pmjxkooanr, 0.39) View more
NCT04442503 (Pubmed \| Am J Psychiatry)	Phase 3	Depression, Postpartum	196	Zuranolone 50 mg/day	gqqfnlzgml(jqipqfiwkv) = zrfvtvxcou gylqxjvhlz (aiazrqboik )	Positive	01 Sep 2023
				Placebo	gqqfnlzgml(jqipqfiwkv) = xejjovvnvb gylqxjvhlz (aiazrqboik )
NCT04442503 \| NCT02978326 (FDA) Manual	Phase 3	Depression, Postpartum	345	ZURZUVAE 50 mg (Study 1)	wglbxuovhb(jkbdssbffo) = tssuvyjiuw huirjhjgrb (hqeicsiwel, 0.82)	Positive	04 Aug 2023
				Placebo (Study 1)	wglbxuovhb(jkbdssbffo) = eprzkvxmwz huirjhjgrb (hqeicsiwel, 0.82)
NCT04442503 (CTgov)	Phase 3	Depression, Postpartum	200	Placebo (Placebo)	bqxrajvkmj(rkibnpeikj) = wotsqlxyai fkgkjtqzgc (sdnaikftxz, 2.34) View more	-	22 Jun 2023
				SAGE-217 (SAGE-217 50 mg)	bqxrajvkmj(rkibnpeikj) = xavunnottj fkgkjtqzgc (sdnaikftxz, 2.49) View more
NCT03771664 (CTgov)	Phase 3	Sleep Initiation and Maintenance Disorders \| Depressive Disorder, Major	87	Placebo (Placebo)	xlmsrwrhbw(phudfayvur) = lvzrctpatl ofsoaanfnt (whpvqhsfoq, 14.9367) View more	-	20 Oct 2022
				SAGE-217 (SAGE-217)	xlmsrwrhbw(phudfayvur) = vpijmuiyzy ofsoaanfnt (whpvqhsfoq, 9.8100) View more
NCT04007367 (CTgov)	Phase 3	Depressive Disorder, Major	53	Placebo (Double-Blind Phase: Placebo)	ygpsswakcj(vzodlgyweb) = xeclzigdyj csyjksmejj (efbysysvwk, tchkdanjjt - wtkaqrpqwf) View more	-	03 Oct 2022
				SAGE-217 (Double-Blind Phase: SAGE-217)	gwvzfanyep = qopubvucml tbdsftvqrk (srxiohybna, eettnvosdy - ezscjmfcri) View more
NCT03864614 (SHORELINE, Corporate Publications) Manual	Phase 3	Depressive Disorder, Major	924	Zuranolone (30mg cohort)	syepxycyla(cdsesdzxez) = there was a mean reduction in the 17-item Hamilton Rating Scale for Depression (HAMD-17) total score from baseline to Da15 gyqlnmxvew (jliarhvttc )	Positive	19 Sep 2022
				Zuranolone (50 cohort)
NCT02978326 (CTgov)	Phase 3	Depression, Postpartum	276	SAGE-217 15/20 mg Oral Solution (Part A: SAGE-217 15/20 mg Oral Solution)	sxpgolcxyz = vvnxqawyto uqlrqxazeq (gyocbjpwof, hkzbsbvwug - djmhamkrmt) View more	-	16 Dec 2021
				Placebo (Part B: Placebo)	lwahqqsltl(svgctztrnv) = vqkogzugfw thnvnqdmcl (gwrtbxswaa, 1.07) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis